Last Modified: August 22, 2011
Classification: Tyrosine Kinase Inhibitor
Gefitinib is a small molecule drug that inhibits tyrosine kinase, an enzyme associated with the human Epidermal Growth Factor Receptor (EGFR). By inhibiting this enzyme, gefitinib prevents EGFRs from stimulating the uncontrolled growth of cells that contributes to tumor growth.
Gefitinib comes as a tablet to take by mouth. It is taken with or without food once a day. Take gefitinib at around the same time every day. If you miss a dose, you should take it as soon as you remember. However, if it is less than 12 hours until the next dose, you should not take the missed dose. Do not take a double dose to make up for the missed dose.
There are a number of things you can do to manage the side effects of Gefitinib. Talk to your doctor or nurse about these recommendations. They can help you decide what will work best for you. These are some of the most common side effects:
EGFR inhibitors, such as gefitinib, have some unique nail and skin side effects that you may develop. Patients may develop a rash. While this rash may look like acne, it is not, and should not be treated with acne medications. The rash may appear red, swollen, crusty and dry and feel sore. You may also develop very dry skin, which may crack, be itchy or become flaky or scaly. The rash my be the worst during the first few weeks of treatment, but may continue until treatment is stopped. Tips for managing your skin include:
While receiving gefitinib, you may develop an inflammation of the skin around the nail bed/cuticle areas of toes or fingers, which is called paronychia. It can appear red, swollen or pus filled. Nails may develop "ridges" in them or fall off. You may also develop cuts or cracks that look like small paper cuts in the skin on your toes, fingers or knuckles. These side effects may appear several months after starting treatment, but can last for many months after treatment stops.
While receiving gefitinib, your eyelashes may grow very fast, become very long and bother your eyes. You may develop inflammation at the site where your eyelashes come out of the eyelid. You may develop dry eyes. These tend to resolve once treatment is stopped.
Take anti-nausea medications as prescribed. If you continue to have nausea or vomiting, notify your doctor or nurse so they can help you manage this side effect. In addition, dietary changes may help. Avoid things that may worsen the symptoms, such as heavy or greasy/fatty, spicy or acidic foods (lemons, tomatoes, oranges). Try antacids, (e.g. milk of magnesia, calcium tablets such as Tums), saltines, or ginger ale to lessen symptoms. Read the Nausea & Vomiting Tip Sheet for more suggestions.
Call your doctor or nurse if you are unable to keep fluids down for more than 12 hours or if you feel lightheaded or dizzy at any time.
While on cancer treatment you may need to adjust your schedule to manage fatigue. Plan times to rest during the day and conserve energy for more important activities. Exercise can help combat fatigue; a simple daily walk with a friend can help. Talk to your healthcare team and see OncoLink's section on fatigue for helpful tips on dealing with this side effect.
Your oncology team can recommend medications to relieve diarrhea. Also, try eating low-fiber, bland foods, such as white rice and boiled or baked chicken. Avoid raw fruits, vegetables, whole grain breads, cereals and seeds. Soluble fiber is found in some foods that absorbs fluid and can help relieve diarrhea. Foods high in soluble fiber include: applesauce, bananas (ripe), canned fruit, orange and grapefruit sections, boiled potatoes, white rice and products made with white flour, oatmeal, cream of rice, cream of wheat, and farina. Drink 8-10 glasses on non-alcoholic, un-caffeinated fluid a day to prevent dehydration. Read Low Fiber Diet for Diarrhea for more tips.
Jul 29, 2011 - The abundance of epidermal growth factor receptor (EGFR) mutations in advanced non-small-cell lung cancer is associated with a response to treatment with the EGFR-tyrosine kinase inhibitor, gefitinib, according to a study published online July 25 in the Journal of Clinical Oncology.
Jul 29, 2011
Oct 14, 2013
Jun 24, 2010